What do systematic reviews say?

Vitamin D vs placebo or no intervention

It is very uncertain whether vitamin D changes adverse effect: hypercalcaemia As defined by trialistsTime frame:… compared with placebo or no intervention (very low certainty).

• Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years… 2020 · Cochrane Headline outcomes only
  RR 0.82 [0.35, 1.9]
  2 studies · 367 participants
  Very low

Vitamin D vs placebo or no intervention

The review found no eligible studies for this question.

• Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin D vs placebo or no intervention

The review found no eligible studies for this question.

• Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin D (higher dose) vs vitamin D (lower dose)

• Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 283 participants
  Very low

Vitamin D (higher dose) vs vitamin D (lower dose)

• Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 105 participants
  Low

NSAIDs vs placebo

• Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 226 participants
  Moderate

NSAIDs vs placebo

• Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Moderate

NSAIDs vs placebo

• Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 79 participants
  Moderate

NSAIDs vs placebo

• Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 226 participants
  Moderate

NSAIDs vs placebo

• Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Moderate

NSAIDs vs placebo

• Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 79 participants
  Moderate

NSAIDs vs placebo

Summary of findings: non‐steroidal anti‐inflammatory drugs showed no clear difference in proportion with at least 1 hospital admission compared with placebo (moderate certainty).

• Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  OR 0.61 [0.37, 1.01]
  4 studies · 286 participants
  Moderate

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  33 studies · 3389 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  27 studies · 3089 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 152 participants
  Very low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 522 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1052 participants
  Low

Intervention not reported

The intervention may leads to higher number achieving target Hb or increase ≥1 g/dL (low certainty).

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  RR 1.71 [1.43, 2.04]
  13 studies · 2206 participants
  Low

Intervention not reported

• Parenteral versus oral iron therapy for adults and children with chronic kidney disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  31 studies · 3373 participants
  Low

5‐ASA vs no treatment

5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  RR 0.71 [0.46, 1.1]
  110 participants
  Low